Evommune, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureOct 1 →Insiders4 insiders bought $70.0M in 5 open-market buys. 6 insiders sold $2.3M, all 9 sales on a 10b5-1 plan.→HoldersEQT Fund Management S.a r.l. 14.6%Ra 9.6%Pivotal bioVenture Partners Investment Advisor 5.3%→Financing →PeersClosest companies: SEPN, APGE, MBX→
From the filings
Figures
- Revenue
- $10.0Mlast 12 months
- Net income
- −$94.7Mlast 12 months
- Operating cash flow
- −$80.0Mlast 12 months
- Cash and equivalents
- $60.0Mat the last balance sheet
- Shares outstanding
- 36.3M shareson issue